{"id":"non-immunogenic-staphylokinase","safety":{"commonSideEffects":[{"rate":"null","effect":"Hemorrhage"},{"rate":"null","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process is crucial in treating conditions associated with excessive clotting, such as pulmonary embolism and deep vein thrombosis. Unlike traditional staphylokinase, non-immunogenic staphylokinase has been engineered to minimize the risk of an immune response, allowing for repeated administration if necessary.","oneSentence":"Non-immunogenic staphylokinase is a genetically engineered enzyme that catalyzes the conversion of plasminogen to plasmin, thereby dissolving blood clots.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:18.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute ischemic stroke"},{"name":"Treatment of pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT07324837","phase":"PHASE3","title":"Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset","status":"NOT_YET_RECRUITING","sponsor":"Supergene, LLC","startDate":"2026-02-01","conditions":"Ischemic Stroke, Acute","enrollment":990},{"nctId":"NCT06707987","phase":"","title":"Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)","status":"COMPLETED","sponsor":"Supergene, LLC","startDate":"2021-03-01","conditions":"Acute Ischemic Stroke","enrollment":23250},{"nctId":"NCT06362746","phase":"PHASE3","title":"Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism","status":"RECRUITING","sponsor":"Supergene, LLC","startDate":"2024-05-23","conditions":"Pulmonary Embolism","enrollment":486},{"nctId":"NCT05372718","phase":"PHASE3","title":"Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial","status":"RECRUITING","sponsor":"Supergene, LLC","startDate":"2022-12-26","conditions":"Acute Limb Ischemia","enrollment":170},{"nctId":"NCT07245927","phase":"","title":"Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism","status":"RECRUITING","sponsor":"Supergene, LLC","startDate":"2025-06-01","conditions":"Pulmonary Embolism Acute Massive","enrollment":20000},{"nctId":"NCT04688320","phase":"PHASE3","title":"Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE","status":"COMPLETED","sponsor":"Supergene, LLC","startDate":"2020-12-15","conditions":"Massive Pulmonary Embolism","enrollment":310},{"nctId":"NCT05135546","phase":"PHASE2, PHASE3","title":"Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial","status":"TERMINATED","sponsor":"Supergene, LLC","startDate":"2021-12-27","conditions":"COVID-19","enrollment":4},{"nctId":"NCT05697575","phase":"","title":"Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","status":"UNKNOWN","sponsor":"National Society for Neurosonology and Cerebral Circulation","startDate":"2023-02-01","conditions":"Acute Stroke","enrollment":336}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fortelyzin®"],"phase":"phase_3","status":"active","brandName":"non-immunogenic staphylokinase","genericName":"non-immunogenic staphylokinase","companyName":"Supergene, LLC","companyId":"supergene-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Non-immunogenic staphylokinase is a genetically engineered enzyme that catalyzes the conversion of plasminogen to plasmin, thereby dissolving blood clots. Used for Treatment of acute ischemic stroke, Treatment of pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}